Tag: Pharmaceutical Industry

EMA survey displayed gaps in pharma industry preparedness for Brexit

european medicines agency
Regulatory authorities and marketing authorisation holders both play an important part in preparing for the consequences of Brexit to safeguard the continuous supply of medicines after the withdrawal of the UK from EU.

GlobalData named the top 25 pharma companies by market capitalization

GlobalData has tracked the market capitalization performance of the Top 25 pharma companies for the quarter ending 31 March, 2018 compared to 2017 revealing a number of interesting insights.

Deloitte’s recent survey reflects the increasing role of real-world evidence

Deloitte’s real-world evidence (RWE) benchmarking survey studies how biopharma companies are using RWE, what they are investing in, areas of impact, and the hurdles to successful adoption.

Global biotech conference started in South Korea

The 2018 Global Bio Conference kicked off in Seoul, bringing together biotech regulators and industry experts from around the world to support the growth and overseas expansion of South Korea’s biopharmaceutical businesses.

China will conduct regulatory trainings for Indian pharma companies

china street
China has agreed to conduct specific training programmes for Indian pharmaceutical companies to understand their regulatory system, which will promote India's exports from the sector.

China’s domestic pharma industry driving huge machinery influx at P-MEC China

45,000 industry experts attend as intelligent manufacturing and new environmental policies identified as key medium term trends

New digital platform is expected to revolutionize drug discovery

The launch date of the new iPlexus will be on June 30, 2018. The platform is expected to transform the exchange of research work not only in preclinical life research but also in drug discovery.

EU Commission offers a proposal to adjust intellectual property rules

EU flag
The EU Commission proposed to adjust intellectual property rules to help Europe's pharmaceutical companies tap into fast-growing global markets and foster jobs, growth and investments in the EU.

Russian pharmaceutical market: stability in unstable environment

According to DSM Group, in 2017, the Russian market was worth 1629 billion rubles, which 8% higher than in 2016. For the first time in three years, the market grew in dollar- and euro-denominated terms.

Sanctions will not be imposed on medicines that are not manufactured in Russia

Counter-sanctions against the United States should not affect the medicines that are not manufactured in Russia, said the acting Russian Minister of Industry Denis Manturov.

Samsung BioLogics is concerned about the accusation of accounting fraud

samsung biologics
South Korea’s major biopharmaceutical firm Samsung BioLogics Co., which has been embroiled in an alleged violation of accounting rules, expressed concern over the local financial regulator’s disclosure of sensitive information.

Valeant Pharmaceuticals changes its name to Bausch Health Companies

As part of the name change, the Company will roll out a new corporate brand identity in July 2018, which will include new imagery and web site, and will trade under a new symbol, BHC.

EMA issued its annual report for the year 2017

The 2017 annual report provides an overview of the work of the European Medicines Agency (EMA) and highlights last year’s major achievements in protecting and promoting public and animal health in the European Union (EU).

The second issue of “CIS GMP news” English-language magazine is out

The spring English-language issue of «CIS GMP News» reflects the current state of pharmaceutical industry in Russia and other EAEU member states, and highlights achievements in the area of pharmaceutical manufacturing.

Russian Ministry is against imposing a ban on TV advertising of medicines

The initiative to ban TV advertising of medicines is extremely harmful and dangerous, because it may be motivated by concealed interests of pharmaceutical companies, said Deputy Minister of Communications and Mass Media.

Sofinnova Partners sets up a new fund to invest in biopharmaceutical sector

Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, announced the launch of Sofinnova Crossover I with €275 million, above the original first close target of €250 million.